On the stock market since 1997, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
No real growth (-3% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 32% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 11% a year on average.
Sales run at $26.4M a year. A small number, but proof the product has real buyers.
It pays out $0.62 per share each year — regular cash for whoever holds the stock.
A loss of $27.6M against $26.4M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, MHN sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: MHN is a high-risk stock — not yet profitable, and its future rides on its product catching on.